A biopharmaceutical, also known as a biologic drug product, is a pharmaceutical drug that has been derived from biological sources. They can be synthetically synthesized, extracted, or produced using a biological process. A bi-specific drug is made from more than one biological source and has specific properties that can be used to treat a specific disease or health condition. These drugs are used to treat diseases and treat disorders.
A bi-specific biologic drug is produced by instructing a cell to produce a large amount of a specific molecule or protein. The isolated molecules are then purified and used as the active ingredient in a biologic drug. They are not uniformly sized and contain tens of thousands of atoms. Additionally, they are susceptible to temperature changes and can cause adverse side effects. However, they are the most effective treatment for a number of serious diseases.
Get PDF Sample Copy of Report (Including Full TOC, List of Tables & Figures, Chart) @ https://www.coherentmarketinsights.com/insight/request-sample/4145
Global Cancer Biologics Market Drivers
Increasing approvals of biologic drug by regulatory authorities for the treatment of cancer is driving growth of global cancer biologics market. For instance, in 2018, the U.S Food and Drug Administration (FDA) approved blinatumomab, for the patient suffering from B-cell precursor acute lymphoblastic leukemia, which show reduction in the severity of the disease, as the minimal residual disease (MRD) is found to be greater than or equal to 0.1%. Furthermore, in 2018, U.S FDA approved Cemiplimab-rwlc, for the treatment metastatic advanced stage cutaneous squamous cell cancer. The recommended Cemiplimab-rwlc dose for the patient is 350 mg, which is administrated as intravenous infusion over 30 minutes, in every three weeks.
Moreover, in January 2020, F. Hoffmann-La Roche AG announced about its submission of supplemental biological license to U.S Food and Drug Administration (FDA) for Tecentriq (atezolizumab), in combination with Avastin (bevacizumab) drug for most common form of liver cancer. Thus, growing number of regulatory approvals of biologic drug for the treatment of cancer is driving growth of the cancer biologics market.
Global Cancer Biologics Market Restraints
However, high cost associated with cancer biologic drug is one of the major restraint that is expected to hamper the global cancer biologics market growth. For instance, cost of blinatumomab is US$ 17,800 per year. Furthermore, side effects associated with consumption cancer biologic drug such as allergic reactions, injection site reactions, diarrhea, weakness, nausea, vomiting, and rash yet remains another factor hampering the global cancer biologics market growth.
Global Cancer Biologics Market Regional Analysis
North America is expected to account for highest market share in the global cancer biologics market, due to growing prevalence of cancer in the region. For instance, in 2019, in the U.S, according to the American Cancer Society’s (ACS), around 1,762,450 new cancer cases were diagnosed, and 606,880 new cancer deaths were reported.
Furthermore, growing drug approvals for the treatment of metastatic merkel cell carcinoma (MCC) by the company is driving the global cancer biologic market growth. For instance, in 2018, pembrolizumab received approval from the U.S. Food and Drug Administration (FDA) for the treatment of patients suffering from metastatic Merkel cell carcinoma (MCC).
Europe is projected to account for second highest market share in the global cancer biologics market, due to grpwing prevalence of cancer in Europe region. For instance, in 2018, around 3.9 million of cancer with new cases excluding non-melanoma skin cancer, and 1.9 million death from cancer were reported by the International Agency for Research on Cancer (IARC), in collaboration with the European Network of Cancer Registries (ENCR, as well as the European Commission’s Joint Research Centre (JRC).
Moreover, Asia Pacific is projected to exhibit CAGR over the forecast period due to the increasing approval of drugs by regulatory bodies for the treatment of Hodgkin’s disease (blood cancer) by the company. For instance, in 2018, National Medical Products Administration (NMPA) of China approved Sintilimab injection, which is sold under the brand name Tyvyt, and was jointly announced by Innovent Biologics, Inc. and Eli Lilly and Company. Sintilimab injection is used for the treatment of Hodgkin’s disease (blood cancer), and is fully human IgG4 monoclonal antibody.
Request Here For PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/4145
Global Cancer Biologics Market Key Players
Key players operating in the global cancer biologic market are Merck & Co., Inc., Novartis International AG, F. Hoffmann-La Roche AG, Eli Lilly and Company, Bristol-Myers Squibb Company, Amgen Inc., Pfizer Inc., Sanofi S.A., Bayer AG, EnGeneIC Ltd, and GlaxoSmithKline PLC.
On the basis of product, the global cancer biologics market is segmented into:
- Monoclonal Antibodies
- Naked Monoclonal Antibodies
- Conjugated Monoclonal Antibodies
- Chemo labeled Antibodies
- Radiolabeled Antibodies
- Bispecific Monoclonal Antibodies
- Cytokine-Based Immunotherapy
- Cancer Vaccines
- Treatment Vaccines
- Preventive Vaccines
- CAR-T Cell Therapy
- Immune Checkpoint Inhibitors
- CTL-4 Checkpoint Inhibitor
- PD-1 & PD-L1 Checkpoint Inhibitor
On the basis of application, the global cancer biologics market is segmented into:
- Non-Small Cell Lung Cancer
- Prostate Cancer
- Breast Cancer
- Acute Myeloid Leukemia
- Multiple Myeloma
- Ovarian Cancer
- Colorectal Cancer
- Gastric Cancers
On the basis of distribution channel, the global cancer biologics market is segmented into:
On the basis of region, the global cancer biologics market is segmented into:
- North America
- Latin America
- Middle East
- Asia Pacific
Buy This Report with Flat USD 2000 Off @ https://www.coherentmarketinsights.com/promo/buynow/4145
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Cancer Biologics Market Size Analysis from 2021 to 2028
11.6 COVID-19 Outbreak: Cancer Biologics Industry Impact
Chapter 2 Global Cancer Biologics Competition by Types, Applications, and Top Regions and Countries
2.1 Global Cancer Biologics (Volume and Value) by Type
2.3 Global Cancer Biologics (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Cancer Biologics Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Cancer Biologics Market Analysis
Chapter 6 East Asia Cancer Biologics Market Analysis
Chapter 7 Europe Cancer Biologics Market Analysis
Chapter 8 South Asia Cancer Biologics Market Analysis
Chapter 9 Southeast Asia Cancer Biologics Market Analysis
Chapter 10 Middle East Cancer Biologics Market Analysis
Chapter 11 Africa Cancer Biologics Market Analysis
Chapter 12 Oceania Cancer Biologics Market Analysis
Chapter 13 South America Cancer Biologics Market Analysis
Chapter 14 Company Profiles and Key Figures in Cancer Biologics Business
Chapter 15 Global Cancer Biologics Market Forecast (2021-2027)
Chapter 16 Conclusions
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027